NeoGenomics Q2 revenue beats estimates, raises outlook

NeoGenomics

28/07/2026 21:16

Overview
Oncology diagnostics firm's Q2 revenue rose 11% yr/yr, beating analyst expectations
Adjusted EPS for Q2 beat consensus
Company raised full-year 2026 revenue and adjusted EBITDA guidance

Outlook
NeoGenomics raises full-year 2026 revenue guidance to $802 mln-$806 mln
Company increases full-year 2026 adjusted EBITDA guidance to $56 mln-$58 mln
NeoGenomics expects full-year 2026 GAAP net loss of $42 mln-$34 mln

Result Drivers
NGS GROWTH - Co said 26% yr/yr growth in next-generation sequencing revenue contributed to overall revenue increase
HIGHER PRICING - Average revenue per clinical test rose 12% to $515, supporting revenue growth
COST DISCIPLINE - Operating expenses fell 19%, mainly due to absence of prior-year impairment charges

Company press release: ID:nBw6VWBT9a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$202 mln
$197 mln (12 Analysts)
Q2 Adjusted EPS
Beat
$0.05
$0.03 (10 Analysts)
Q2 EPS
 
$0.02
 
Q2 Adjusted Net Income
 
$7 mln
 
Q2 Net Income
 
$2 mln
 
Q2 Adjusted EBITDA
 
$14 mln
 
Q2 Gross Profit
 
$92 mln
 
Q2 Operating Expenses
 
$102 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for Neogenomics Inc is $16.00, about 21.8% above its July 27 closing price of $13.14
The stock recently traded at 46 times the next 12-month earnings vs. a P/E of 38 three months ago

Reuters Recommended Reads
July 27 - Champions Oncology Q4 revenue rises; margin improves driven by cost discipline
July 28 - IQVIA raises annual profit forecast on clinical research demand
July 28 - Repligen Q2 revenue beats estimates on higher orders; raises outlook

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)